echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > FDA approves Red Hill's innovative therapy, Talicia, for listing

    FDA approves Red Hill's innovative therapy, Talicia, for listing

    • Last Update: 2021-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    today, Red Hill Biopharma announced that the U.S. FDA has approved the listing of its innovative therapy, Talicia, to treat adult patients infected with Helicobacter pyridosis.Talicia is an FDA-approved helicobacter pyridobacteria removal therapy based on rifabutin designed to address helicobacter pyridosis resistance to antibiotics commonly used in standard care therapies.RedHill plans to bring Talicia to the U.S. market in the first quarter of 2020.Talicia is a new fixed-dose oral capsule formulated with two antibiotics: lifobutin and amoxicillin, and a proton pump inhibitor (PPI) omeprazole. Previously, the FDA has granted Talicia Qualified Infectious Disease Products (QIDP) qualifications, priority review qualifications, and fast-track eligibility.Talicia's approval is based on positive results from two Phase 3 clinical studies. The results of one of the validated Phase 3 trials showed that 84 per cent of patients treated with Talicia had their Helicobacter pyrethrobacteria infection cleared, compared with 58 per cent in the control group, with significant statistical differences.In addition, no resistance to lifobutin, a key component of Talicia's unique formulation, was not detected in the trial. (Drug Information Network)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.